Logo

Oxford Genome Sciences to Evaluate Bayer Diagnostics Breast Cancer Biomarkers

Mar 16, 2005

NEW YORK, March 16 (GenomeWeb News) -Oxford Genome Sciences will use its proteomics platform and its Oxford Genome Anatomy Project to evaluate biomarkers linked to breast cancer for Bayer HealthCare's diagnostics division, the companies said today.

 

Though financial terms of the agreement were not disclosed, Bayer said it "has committed program funding" to Oxford, and agreed to performance-related payments upon achieving certain milestones.

Bayer HealthCare hopes this research will help it discover and develop therapeutic and diagnostic products for breast cancer. 

According to Oxford, the OGAP proteomics database has more than 1 million peptide sequences from approximately 50 different tissues involved in almost 60 different diseases mapped onto 15,000 human genes.

Breaking News
The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.